Cargando…

Correction to: The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion

Detalles Bibliográficos
Autores principales:	Park, Sophie, Kelaidi, Charikleia, Meunier, Mathieu, Casadevall, Nicole, Gerds, Aaron T., Platzbecker, Uwe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944644/ https://www.ncbi.nlm.nih.gov/pubmed/31788722 http://dx.doi.org/10.1007/s00277-019-03874-w

Ejemplares similares

The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion
por: Park, Sophie, et al.
Publicado: (2019)

Lower‐risk myelodysplastic syndromes: Current treatment options for anemia
por: Meunier, Mathieu, et al.
Publicado: (2022)

Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway
por: Balaian, Ekaterina, et al.
Publicado: (2018)

Setting Fire to ESA and EMA Resistance: New Targeted Treatment Options in Lower Risk Myelodysplastic Syndromes
por: Kubasch, Anne Sophie, et al.
Publicado: (2019)

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes
por: Park, Sophie, et al.
Publicado: (2019)

Facing the challenge: Novel treatment options for patients with myelodysplastic syndromes
por: Kubasch, Anne Sophie, et al.
Publicado: (2018)

Which second line treatments after ESA failure?
por: Park, Sophie, et al.
Publicado: (2017)

Current challenges and unmet medical needs in myelodysplastic syndromes
por: Platzbecker, Uwe, et al.
Publicado: (2021)

Extracellular Vesicles and MicroRNA in Myelodysplastic Syndromes
por: Meunier, Mathieu, et al.
Publicado: (2023)

Chronic Myeloid Leukemia in Children and Adolescents: The Achilles Heel of Oncogenesis and Tyrosine Kinase Inhibitors
por: Moschovi, Maria, et al.
Publicado: (2021)

Old Dogs, New Tricks: Revisiting Immune Modulatory Approaches for Myelodysplastic Syndromes
por: Götze, Katharina S., et al.
Publicado: (2018)

Experts Opinion
por: Goldberg, Ivan, et al.
Publicado: (2012)

Expert Opinion
Publicado: (1920)

Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape
por: Schwind, Sebastian, et al.
Publicado: (2021)

More Expert Opinion
Publicado: (1920)

Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome
por: Ma, Wanlong, et al.
Publicado: (2010)

Patellofemoral arthroplasty: expert opinion
por: Hoogervorst, Paul, et al.
Publicado: (2022)

Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice
por: Weidner, Heike, et al.
Publicado: (2022)

Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
por: Santini, Valeria, et al.
Publicado: (2020)

Molecular dissection of engraftment in a xenograft model of myelodysplastic syndromes
por: Meunier, Mathieu, et al.
Publicado: (2018)

Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin
por: Wang, Chen, et al.
Publicado: (2021)

When expert opinion does matter...
por: Delmo Walter, E M, et al.
Publicado: (2012)

Expert opinion about osteonecrosis of the jaw
por: Lee, Jeong Keun
Publicado: (2017)

Management of Osteoarthritis: Expert Opinion on NSAIDs
por: Magni, Alberto, et al.
Publicado: (2021)

Editorial: Experts' opinion in medicine 2022
por: Bunik, Victoria I.
Publicado: (2023)

Navigating adalimumab biosimilars: an expert opinion
por: Abitbol, Vered, et al.
Publicado: (2023)

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
por: Giagounidis, Aristoteles, et al.
Publicado: (2008)

Lower serum prohepcidin levels associated with lower iron and erythropoietin requirements in hemodialysis patients with chronic hepatitis C
por: Caliskan, Yasar, et al.
Publicado: (2012)

Lenalidomide Induces Lipid Raft Assembly to Enhance Erythropoietin Receptor Signaling in Myelodysplastic Syndrome Progenitors
por: McGraw, Kathy L., et al.
Publicado: (2014)

Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score‐matched analysis
por: Balleari, Enrico, et al.
Publicado: (2019)

Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes
por: Vetro, Calogero, et al.
Publicado: (2022)

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
por: Zeidan, Amer M., et al.
Publicado: (2022)

Language Mapping Using Stereo Electroencephalography: A Review and Expert Opinion
por: Aron, Olivier, et al.
Publicado: (2021)

Revenue assurance : expert opinions for communications providers
por: Priezkalns, Eric, et al.
Publicado: (2011)

Benefits of genome-edited crops: expert opinion
por: Lassoued, Rim, et al.
Publicado: (2019)

Placebo effects in allergen immunotherapy: an experts’ opinion
por: Frew, Anthony J., et al.
Publicado: (2018)

Heart Rate in Hypertension: Review and Expert Opinion
por: Dalal, Jamshed, et al.
Publicado: (2019)

Expert opinions on immunotherapy for patients with colorectal cancer
por: Wang, Feng, et al.
Publicado: (2020)

Expert opinions on the regulation of plant genome editing
por: Lassoued, Rim, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tj6rnguv1srt0i30mm0m1m9mhr